Reproducibility of serologic assays for influenza virus A (H5N1)

Emerging Infectious Diseases

Volumn 15, Issue 8, 2009, Pages 1250-1259

  Stephenson, Iain ^a,g   Heath, Alan ^b   Major, Diane ^b   Newman, Robert W ^b   Hoschler, Katja ^c   Junzi, Wang ^f   Katz, Jacqueline M ^d   Weir, Jerry P ^e   Zambon, Maria C ^c   Wood, John M ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^g LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CLADISTICS; CLINICAL ARTICLE; GOOD LABORATORY PRACTICE; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA; INFLUENZA VIRUS A H5N1; INTERNATIONAL STANDARD UNIT; NONHUMAN; REPRODUCIBILITY; SEROLOGY; STANDARD; VIRUS NEUTRALIZATION; WORLD HEALTH ORGANIZATION; ANIMAL; BLOOD; COMMUNICABLE DISEASE; EVALUATION; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; LABORATORY; LABORATORY DIAGNOSIS; METHODOLOGY; SERODIAGNOSIS; SHEEP; STATISTICS; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; COMMUNICABLE DISEASES, EMERGING; FALSE POSITIVE REACTIONS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LABORATORIES; NEUTRALIZATION TESTS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SEROLOGIC TESTS; SHEEP; WORLD HEALTH ORGANIZATION;

EID: 68049147167     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1508.081754     Document Type: Article

References (20)

1. Zambon M. Laboratory diagnosis of influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Influenza. Oxford (UK): Blackwell Publishing; 1997. p. 123-56.
2. Potter CW. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35:69-75.
3. Wood JM, Newman RK, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol (Basel). 2003;115:9-16.
4. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines, March 12, 1997; CPMP/BWP/214/96 [cited 2009 May 5]. Available from http://www.emea.europa.eu/ pdfs/human/bwp/021496en.pdf
5. US Food and Drug Administration. Guidance for industry. Clinical data needed to support the licensure of pandemic influenza vaccines [cited 2009 May 5]. Available from http://www.fda.gov/cber/gdlns/ panfluvac.pdf
6. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: randomised trial of two potential vaccines against H5N1. Lancet. 2001;357:1937-42. DOI: 10.1016/S0140-6736(00)05066-2
7. Rowe T, Abernathy RA, Hu-Primmer J, Thompson XX, Lu X, Lim W, et al. Detection of antibody to avian influenza (H5N1) virus in human sera by using a combination of serological assays. J Clin Microbiol. 1999;37:937-43.
8. Stephenson I, Wood J, Nicholson K, Zambon MC . Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol. 2003;70:391-8. DOI: 10.1002/jmv.10408
9. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/duck/ Singapore/97 H5N3 vaccine. Virus Res. 2004;103:91-5. DOI: 10.1016/j.virusres.2004.02.019
10. Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: international collaborative study. Vaccine. 2007;25:4056-63. DOI: 10.1016/j.vaccine.2007.02.039
11. Wood JM, Gaines-Das R, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine. 1994;12:167-75. DOI: 10.1016/0264-410X(94)90056-6
12. Ferguson M, Heath A. Report of a collaborative study to calibrate the second international standard for parvovirus B19 antibody. Biologicals. 2004;32:207-12.
13. World Health Organization. Norms and standards: quality, safety and efficacy of medicines [cited 2009 May 5]. Available from http:// www.who.int/medicines/areas/quality-safety/en
14. The World Health Organization Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis. 2005;11:1515-22.
15. World Health Organizaion. WHO Expert Committee on Biological Standardization [cited 2009 May 5]. Available from http://www. who.int/biologicals/expert-committee/TRS932CVR%20with%20 full%20Texts.pdf
16. World Health Organizaion. WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines [cited 2009 May 5]. Available from http:// www.who.int/vaccine-research/ diseases/influenza/ECBS-2005- Annex-5-Influenza.pdf
17. Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol. 1990;28:1308-13.
18. World Health Organization. WHO manual on animal influenza diagnosis and surveillance [cited 2009 May 5]. Available from http:// www.who.int/vaccine- research/diseases/influenza/WHO-manual- on-animal-diagnosis-and-surveillance- 2002-5.pdf
19. Kayali G, Setterquist SF, Capuano AW, Myers K, Gill J, Gray G. Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays. J Clin Virol. 2008;43:73-8. DOI: 10.1016/j.jcv.2008.04.013
20. Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005;23:1414-25. DOI: 10.1016/j.vaccine.2004.08.053